Hasle H
Department of Oncology and Radiotherapy, University Hospital of Odense, Denmark.
Cancer Chemother Pharmacol. 1990;27(1):76-8. doi: 10.1007/BF00689281.
Acute cerebellar toxicity with ataxia and dysarthria is a well-known side effect during high-dose cytarabine therapy. Dose, age, previous neurological disorders, hepatic dysfunction, and renal insufficiency have been inconsistently reported as risk factors. The present paper presents a patient with renal insufficiency who developed severe cerebellar toxicity following treatment with a dose of cytarabine (8 g/m2 over 5 days) not generally expected to be associated with neurotoxicity. Together with a review of the literature, the present case gives evidence of renal insufficiency as a major risk factor in the development of cerebellar toxicity during cytarabine therapy. Reduced doses of cytarabine should be considered in patients with renal impairment.
急性小脑毒性伴共济失调和构音障碍是大剂量阿糖胞苷治疗期间众所周知的副作用。剂量、年龄、既往神经系统疾病、肝功能不全和肾功能不全被不一致地报道为危险因素。本文介绍了一名肾功能不全患者,在接受了通常预计不会与神经毒性相关的阿糖胞苷剂量(5天内8 g/m²)治疗后发生了严重的小脑毒性。结合文献综述,本病例证明肾功能不全是阿糖胞苷治疗期间小脑毒性发生的主要危险因素。对于肾功能损害患者,应考虑降低阿糖胞苷剂量。